5 / 16
Page 55
Notes:
conferenceseries
.com
September 25-26, 2017 Chicago, USA
3
rd
International Conference on
Parkinson’s disease and Movement Disorders
Volume 7, Issue 5 (Suppl)
J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460
Parkinson 2017
September 25-26, 2017
9-tert-butyl-apomorphine (DTBA) as an effective soluble compound with antioxidant activity for
treatment of experimental Parkinsonism
G Shilau
and
O Shadiro
Belarussian State University, Belarus
Objective:
To evaluate antiparkinsonic effect of the investigated compound were used two different model of experimental
Parkinsonism in white rats: 1
st
– classical model with overdosege of neuroleptic drugs and 2
nd
– new one, with injection the
initiator free-radical oxidation (FRO), FRO - Fe-ascorbate mixture, into
substantia nigra
of the brain.
Background:
One of the causes of Parkinsonism might be activation of lipids peroxidation (LPO). But there might take place
and other FRO initiator reactions, apart from LPO inhibition, that should also be considered – of radical fragmentation
processes. The bifunctional organic compounds like dopamine in particularly can undergo FRO, that is reactions of radical
fragmentation. In former investigations we were found, that the products of free-radical oxidation (FRO) of dopamine on
adding Fe-ascorbate
in vitro
resulted in predominant formation 4-(2-aminoethyl)-benzoquinone-l,2 along with other products.
Results:
Treatment of dopamine with Fe-ascorbate mixture resulted in predominant formation 4-(2-aminoethyl)-
benzoquinone-l, 2 along with other products. The new fenol’s derivative DTBA inhibit FRO of dopamine
in vitro
: Antioxidant
activity of DTBA in 10 times exceed the same one of dibunolum. This compound (DTBA) has not negative reaction (vomiting,
nausea) that caused by Apomorphine. Animals treated with the new phenol derivative DTBA demonstrated considerably faster
recovery from catalepsy.
Conclusions:
In the mechanism of Parkinsonism development an important role may belongs not only LPO but FRO (that is
reactions of radical fragmentation) of dopamine initiated by non-heme Fe and phenol derivatives with АО-activity might be
used as affective means for the treatment of Parkinsonism.
Biography
G Shilau has completed his PhD at age of 29 years old from Byelorussian State Medical University. He worked as Senior Scientific Worker in the Laboratory of The
Biochemistry of Neurohormones over Mention University and then as leading Scientific Worker, Central Scientific-Investigating Laboratory of Byelorussian Medical
Postgraduate Academia. Currently, he works as deputy Director of the Center of Medical Information EOCEN and continues his scientific work in close cooperation
with Laboratory of free-radical process chemistry of the Research Institute of Physical Chemical Problems of the Belarusian State University. He has published
more than 40 papers in reputed journals.
george_shilau@mail.ruG Shilau et al., J Alzheimers Dis Parkinsonism 2017, 7:5 (Suppl)
DOI: 10.4172/2161-0460-C1-031